Status:
RECRUITING
KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models
Lead Sponsor:
Known Medicine, Inc.
Collaborating Sponsors:
M.D. Anderson Cancer Center
Duke Cancer Institute
Conditions:
Cancer
Predictive Cancer Model
Eligibility:
All Genders
18+ years
Brief Summary
This study will assess the ability of the Known Medicine platform to predict the efficacy of certain cancer drug treatments and to validate that tumor organoid drug sensitivity is representative of pa...
Detailed Description
This is a non-interventional clinical study in which (1) cancer tissue that has been resected, biopsied, or drained due to malignant pleural effusion and that is left remaining after (or is not being ...
Eligibility Criteria
Inclusion
- A demonstrated primary solid cancer for which it is medically indicated and planned to be surgically resected, biopsied, or drained (via malignant pleural effusion).
- The ability to ship the tissue sample within 24 hours of removal from the patient.
- Signed and dated consent to giving tissue as well as allowing for de-identified medical history information regarding administered treatments and treatment outcomes to be shared.
- over 18 years of age
Exclusion
- Presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation in the opinion of the Investigator.
Key Trial Info
Start Date :
January 12 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT05338073
Start Date
January 12 2021
End Date
January 31 2026
Last Update
April 24 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
2
Duke Cancer Institute
Durham, North Carolina, United States, 27710
3
MD Anderson Cancer Center
Houston, Texas, United States, 77030